Viking Therapeutics Reports $183.2 Million Third-Quarter Net Loss
The company reported no revenue and diluted loss per share of $1.55, compared with a $90.8 million net loss and $0.81 diluted loss per share a year earlier.
Viking Therapeutics reported no revenue and a net loss of $183.2 million for the third quarter of 2026, compared with a $90.8 million loss in the year-earlier quarter. Diluted loss per share was $1.55, versus $0.81.Financial HighlightsBusiness HighlightsOriginal SEC Filing: Viking Therapeutics, Inc…